reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025 Successful completion of €30 Million capital increase, with strong international demand and oversubscriptionAwarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III Results of observational clinical study on Phelan-McDermid syndr...
ORYZON Awarded €13.26 Million Through the First Important Project of C...
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project) Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstatOryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancersFunding covers 64% of Oryzon’s VANDAM project total budg...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Raises €30 Million in Capital Increase
ORYZON Raises €30 Million in Capital Increase Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the offering significantly oversubscribed€15 million anchored by a leading US institutional investorProceeds to fund clinical development and corporate initiatives MADRID and CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion of a €3...
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat New “Decision to grant” communications in Europe and Japan MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that the European Patent Office has issued a “Decision to grant” communication for its European patent application EP20712563.4 relating to vafidemstat. The patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhib...
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clini...
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer In combination with atezolizumab or durvalumabStudy conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON to Provide Corporate Progress Updates at Several Events in Marc...
ORYZON to Provide Corporate Progress Updates at Several Events in March-April BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April. Oryzon will attend the Bio-Europe Spring 2025, which will be held...
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS...
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat A non-interventional study published in Frontiers in PsychiatryPsychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsetsStudy provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traitsConducted in collaboration with the Medical and Molecular Genetics Institute (INGEMM) ...
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression ...
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standardsOryzon moves forward with plans to submit Phase III protocol to the FDA in 1H 2025 MADRID and CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, O...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces the Voting Results of February 2025 Extraordinary Gen...
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share ...
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024 Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data from REIMAGINE proof-of-concept Phase IIa trial published in Psychiatry and Clinical NeurosciencesContinues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophreniaFirst patients dosed in Investigator-initiated Phase I study of iadade...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Resu...
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) Vafidemstat demonstrated a relevant clinical benefit in reducing agitation/aggression across all studied patient populations Data was seminal to start further clinical development in BPDAfter an informative Phase IIb in BPD...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new members will be add...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.